

Attorney Docket No.: 6535.200-US  
USSN: 10/671,064  
Filed: September 25, 2003  
Inventor: Christensen et al.  
Via Facsimile No.: 571-273-8300

**Listing of Claims**

**Claim 1 (Currently Amended)** A process for purifying a fermentation-derived product, said process comprising microfiltration of a fermentation broth containing the product at a microfiltration temperature within the range from 66 °C to 90 °C.

**Claim 2 (Previously Presented)** The process according to claim 1, wherein said microfiltration is performed in the absence of activated carbon.

**Claim 3 (Previously Presented)** The process according to claim 1, wherein the microfiltration temperature is within the range from 70 °C to 90 °C.

**Claim 4 (Previously Presented)** The process according to claim 1, wherein the microfiltration temperature is within the range from 70 °C to 80 °C.

**Claim 5 (Previously Presented)** The process according to claim 1, wherein the microfiltration is performed as a cross flow microfiltration.

**Claim 6 (Previously Presented)** The process according to claim 5, wherein the microfiltration process is performed with a vibrating microfiltration membrane.

**Claim 7 (Previously Presented)** The process according to claim 5, wherein the microfiltration process is performed with backshock.

**Claim 8 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is performed using a microfiltration membrane formed from a material selected from the group consisting of natural polymers, synthetic polymers, ceramics, metals and mixtures thereof

Attorney Docket No.: 6535.200-US  
USSN: 10/671,064  
Filed: September 25, 2003  
Inventor: Christensen et al.  
Via Facsimile No.: 571-273-8300

**Claim 9 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is performed using a polysulphone membrane.

**Claim 10 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is performed as a batch process.

**Claim 11 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is performed as a continuous process.

**Claim 12 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is followed by an ultrafiltration process.

**Claim 13 (Previously Presented)** The process according to claim 12, wherein the cut-off value of the ultrafiltration membrane is lower than four times the molecular weight of the fermentation-derived product.

**Claim 14 (Previously Presented)** The process according to claim 12, wherein the cut-off value of the ultrafiltration membrane is lower than twice the molecular weight of the fermentation-derived product.

**Claim 15 (Previously Presented)** The process according to claim 12, wherein the cut-off value of the ultrafiltration membrane is lower than the molecular weight of the fermentation-derived product.

**Claim 16 (Previously Presented)** The process according to claim 1, wherein the microfiltration process is followed by at least one chromatographic step or at least one precipitation step.

Attorney Docket No.: 6535.200-US  
USSN: 10/671,064  
Filed: September 25, 2003  
Inventor: Christensen et al.  
Via Facsimile No.: 571-273-8300

Claim 17 (Currently Amended) The process according to claim 1, wherein the product is at temperatures higher than ~~60~~ 66 °C for less than 60 minutes.

Claim 18 (Currently Amended) The process according to claim 1, wherein the product is at temperatures higher than ~~60~~ 66 °C for less than 30 minutes.

Claim 19 (Currently Amended) The process according to claim 1, wherein the product is at temperatures higher than ~~60~~ 66 °C for less than 15 minutes.

Claim 20 (Currently Amended) The process according to claim 1, wherein the product is at temperatures higher than ~~60~~ 66 °C for less than 10 minutes.

Claim 21 (Previously Presented) The process according to claim 1, wherein the product is a protein.

Claim 22 (Previously Presented) The process according to claim 21, wherein said protein is a microbially derived protein.

Claim 23 (Previously Presented) The process according to claim 22, wherein the host cell producing said protein is selected from the group consisting of E. coli, Saccharomyces, Pichia, Candida and Kluyveromyces.

Claim 24 (Previously Presented) The process according to claim 22, wherein said protein is a pharmaceutical protein or a precursor thereof.

Claim 25 (Previously Presented) The process according to claim 21 wherein the product is a protein with a molar weight of less than 25000 Dalton.

Attorney Docket No.: 6535.200-US  
USSN: 10/671,064  
Filed: September 25, 2003  
Inventor: Christensen et al.  
Via Facsimile No.: 571-273-8300

**Claim 26 (Previously Presented)** The process according to claim 21 wherein the product is a protein with a molar weight of less than 10000 Dalton.

**Claim 27 (Previously Presented)** The process according to claim 21 wherein the product is a protein with a molar weight of less than 7000 Dalton.

**Claim 28 (Previously Presented)** The process according to claim 21 wherein the product is a protein with a molar weight of less than 4000 Dalton.

**Claim 29 (Previously Presented)** The process according to claim 21, wherein said protein is selected from the group consisting of glucagon-like peptide 1 (GLP-1), glucagon-like peptide 2 (GLP-2), glucagon, trefoil factor (TFF) peptides, interleukins, insulin, albumin, precursors thereof and analogs of any of the foregoing.

**Claim 30 (Previously Presented)** The process according to claim 29, wherein said protein is selected from the group consisting of human insulin, a human insulin precursor, a human insulin analog, a human insulin analog precursor, and Arg<sup>34</sup>-GLP-1(7-37).

**Claim 31 (Previously Presented)** The process according to claim 29, wherein said protein is selected from the group consisting of Arg<sup>34</sup>-GLP-1(7-37), Gly<sup>8</sup>-GLP-1(7-36)-amide, Gly<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>-GLP-1(7-37), Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Asp<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Lys<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>Arg<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-36)-amide, Val<sup>8</sup>His<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>19</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Leu<sup>16</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Tyr<sup>18</sup>Glu<sup>22</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>His<sup>37</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37),

Attorney Docket No.: 6535.200-US  
 USSN: 10/671,064  
 Filed: September 25, 2003  
 Inventor: Christensen et al.  
 Via Facsimile No.: 571-273-8300

Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Glu<sup>22</sup>Val<sup>25</sup>Ile<sup>33</sup>-GLP-1(7-37), Val<sup>8</sup>Trp<sup>16</sup>Glu<sup>22</sup>Val<sup>25</sup>-GLP-1(7-37) and analogs thereof.

Claim 32 (Previously Presented) The process according to claim 29, wherein said protein is selected from the group consisting of: K30R-GLP-2(1-33); S5K-GLP-2(1-33); S7K-GLP-2(1-33); D8K-GLP-2(1-33); E9K-GLP-2(1-33); M10K-GLP-2(1-33); N11K-GLP-2(1-33); T12K-GLP-2(1-33); I13K-GLP-2(1-33); L14K-GLP-2(1-33); D15K-GLP-2(1-33); N16K-GLP-2(1-33); L17K-GLP-2(1-33); A18K-GLP-2(1-33); D21K-GLP-2(1-33); N24K-GLP-2(1-33); Q28K-GLP-2(1-33); S5K/K30R-GLP-2(1-33); S7K/K30R-GLP-2(1-33); D8K/K30R-GLP-2(1-33); E9K/K30R-GLP-2(1-33); M10K/K30R-GLP-2(1-33); N11K/K30R-GLP-2(1-33); T12K/K30R-GLP-2(1-33); I13K/K30R-GLP-2(1-33); L14K/K30R-GLP-2(1-33); D15K/K30R-GLP-2(1-33); N16K/K30R-GLP-2(1-33); L17K/K30R-GLP-2(1-33); A18K/K30R-GLP-2(1-33); D21K/K30R-GLP-2(1-33); N24K/K30R-GLP-2(1-33); Q28K/K30R-GLP-2(1-33); K30R/D33K-GLP-2(1-33); D3E/K30R/D33E-GLP-2(1-33); D3E/S5K/K30R/D33E-GLP-2(1-33); D3E/S7K/K30R/D33E-GLP-2(1-33); D3E/D8K/K30R/D33E-GLP-2(1-33); D3E/E9K/K30R/D33E-GLP-2(1-33); D3E/M10K/K30R/D33E-GLP-2(1-33); D3E/N11K/K30R/D33E-GLP-2(1-33); D3E/T12K/K30R/D33E-GLP-2(1-33); D3E/I13K/K30R/D33E-GLP-2(1-33); D3E/L14K/K30R/D33E-GLP-2(1-33); D3E/D15K/K30R/D33E-GLP-2(1-33); D3E/N16K/K30R/D33E-GLP-2(1-33); D3E/L17K/K30R/D33E-GLP-2(1-33); D3E/A18K/K30R/D33E-GLP-2(1-33); D3E/D21K/K30R/D33E-GLP-2(1-33); D3E/N24K/K30R/D33E-GLP-2(1-33); D3E/Q28K/K30R/D33E-GLP-2(1-33); and precursors thereof

Claim 33 (Previously Presented) The process according to claim 21, wherein said protein is exendin-3, exendin-4 or analogs thereof and precursors of any of the foregoing.

Attorney Docket No.: 6535.200-US  
USSN: 10/671,064  
Filed: September 25, 2003  
Inventor: Christensen et al.  
Via Facsimile No.: 571-273-8300

Claim 34 (Currently Amended) The process according to claim ~~32~~ 33, wherein said protein is ZP-10 (HGEGTFTSDLSKQMEEEAVRLFIEWLKNGGPSSGAPPSKKKKKK-NH2).